Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15470675 | 0.84 | LMNA (0.53) | LMNASMN1; SMN2HTTCA12CA1 | |
| SCHEMBL4069328 | 0.84 | LMNA (0.53) | LMNASMN1; SMN2HTTCA12CA1 | |
| SCHEMBL4409743 | 0.83 | LMNA (0.58) | LMNASMN1; SMN2HTTCA12CA1 | |
| SCHEMBL4061201 | 0.82 | LMNA (0.65) | LMNASMN1; SMN2HTTCA12CA1 | |
| SCHEMBL6284365 | 0.81 | LMNA (0.63) | LMNASMN1; SMN2HTTCA12CA1 | |
| SCHEMBL3798700 | 0.81 | LMNA (0.63) | LMNASMN1; SMN2HTTCA12CA1 | |
| SCHEMBL10873001 | 0.81 | LMNA (0.63) | LMNASMN1; SMN2HTTCA12CA1 | |
| SCHEMBL2795077 | 0.81 | LMNA (0.63) | LMNASMN1; SMN2HTTCA12CA1 | |
| SCHEMBL3798701 | 0.80 | LMNA (0.61) | LMNASMN1; SMN2HTTCA12CA1 | |
| SCHEMBL13055383 | 0.80 | LMNA (0.80) | LMNASMN1; SMN2HTTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1625122-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda San Diego, Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20040254226-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004103993-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | SYRRX, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254226-A1 | Dipeptidyl peptidase inhibitors | DPP3, DPP4, DPP7 | LMNA 3534/4885SMN1; SMN2 3600/4885HTT 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.